Earnings Feed
Start Free
Home/Filings/4/0001256928-09-000013
4//SEC Filing

GALLAGHER ROBERT FRANCIS 4

Accession 0001256928-09-000013

CIK 0001168335other
View on SEC.govCompany Profile

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 8:04 PM ET

Size

50.3 KB

Accession

0001256928-09-000013

Insider Transaction Report

Form 4
Period: 2009-02-25
ABBOTT MEDICAL OPTICS INCEYE
GALLAGHER ROBERT FRANCIS
Executive Vice President
Transactions
  • Disposition to Issuer

    Common Stock

    2009-02-26$22.00/sh−430$9,460→ 0 total
  • Award

    Common Stock

    2009-02-25+1,500→ 1,500 total
  • Tax Payment

    Common Stock

    2009-02-25$22.01/sh−1,245$27,402→ 2,235 total
  • Disposition to Issuer

    Common Stock

    2009-02-26$22.00/sh−2,235$49,170→ 0 total
  • Disposition to Issuer

    Common Stock

    2009-02-26$22.00/sh−4.123$91→ 0 total(indirect: By Trust)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-02-26−20,000→ 0 total
    Exercise: $8.99From: 2006-07-29Exp: 2012-07-29→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-02-26−14,000→ 0 total
    Exercise: $13.85From: 2007-04-29Exp: 2013-04-29→ Common Stock (14,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-02-26−15,000→ 0 total
    Exercise: $33.72From: 2008-05-20Exp: 2014-05-20→ Common Stock (15,000 underlying)
  • Tax Payment

    Common Stock

    2009-02-25$22.01/sh−537$11,819→ 963 total
  • Disposition from Tender

    Common Stock

    2009-02-25$22.00/sh−22$484→ 6,291.383 total
  • Disposition from Tender

    Common Stock

    2009-02-25$22.00/sh−91$2,002→ 6,200.383 total
  • Disposition to Issuer

    Common Stock

    2009-02-26$22.00/sh−4,400.383$96,808→ 1,800 total
  • Disposition to Issuer

    Common Stock

    2009-02-26$22.00/sh−1,156$25,432→ 0 total
  • Award

    Common Stock

    2009-02-25+2,300→ 2,300 total
  • Tax Payment

    Common Stock

    2009-02-25$22.01/sh−823$18,114→ 1,477 total
  • Disposition to Issuer

    Common Stock

    2009-02-26$22.00/sh−1,477$32,494→ 0 total
  • Award

    Common Stock

    2009-02-25+670→ 670 total
  • Tax Payment

    Common Stock

    2009-02-25$22.01/sh−240$5,282→ 430 total
  • Award

    Common Stock

    2009-02-25+600→ 600 total
  • Tax Payment

    Common Stock

    2009-02-25$22.01/sh−215$4,732→ 385 total
  • Disposition to Issuer

    Common Stock

    2009-02-26$22.00/sh−385$8,470→ 0 total
  • Tax Payment

    Common Stock

    2009-02-25$22.01/sh−644$14,174→ 1,156 total
  • Disposition to Issuer

    Common Stock

    2009-02-26$22.00/sh−963$21,186→ 0 total
  • Award

    Common Stock

    2009-02-25+3,480→ 3,480 total
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-02-26−20,000→ 0 total
    Exercise: $38.20From: 2009-02-25Exp: 2015-05-26→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2009-02-26−20,550→ 0 total
    Exercise: $22.94From: 2009-02-25Exp: 2018-05-29→ Common Stock (20,550 underlying)
Footnotes (10)
  • [F1]These shares were tendered to Rainforest Acquisition Inc. ("Purchaser") pursuant to Purchaser?s offer to purchase all of the outstanding shares of Advanced Medical Optics, Inc. (the "Issuer") at a cash purchase price of $22.00 per share, without interest, and subject to any required withholding taxes, subject to the terms described in the Offer to Purchase, filed with the SEC on January 27, 2009, as amended (the "Tender Offer"). Such shares were purchased by Purchaser pursuant to the Tender Offer on February 25, 2009.
  • [F10]This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,431 shares of Abbott Laboratories common stock at an exercise price of $55.92 per share, determined pursuant to a formula set forth in the Merger Agreement.
  • [F2]Includes an aggregate of 4,400.3833 shares of common stock acquired through the issuer's Employee Stock Purchase Plan through February 24, 2009.
  • [F3]These shares were canceled pursuant to the Agreement and Plan of Merger, dated January 11, 2009, by and among Abbott Laboratories, Purchaser and the Issuer (the "Merger Agreement"), in exchange for the right to receive cash payment of $22.00 per share in cash (without interest and subject to any required withholding taxes) at the effective time of the merger.
  • [F4]Shares withheld in satisfaction of tax obligations attributable to the lapse of restrictions on stock award or in satisfaction of tax withholding attributable to vesting and settlement of restricted stock units.
  • [F5]The exempt restricted stock units (previously reported on Table II) vested in full and were settled for shares of Issuer Common Stock in accordance with the terms of the applicable equity plan. At the effective time of the merger, such shares were cancelled pursuant to the Merger Agreement in exchange for the right to receive cash payment of $22.00 per share in cash (without interest and subject to any required withholding taxes).
  • [F6]This previously reported exempt stock option, which had vested as to 100% of the underlying shares in accordance with its terms, and which is held in the name of the reporting person's family trust, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,205 shares of Abbott Laboratories common stock at an exercise price of $21.92 per share, determined pursuant to a formula set forth in the Merger Agreement.
  • [F7]This previously reported exempt stock option, which had vested as to 100% of the underlying shares in accordance with its terms, and which is held in the name of the reporting person's family trust, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 5,744 shares of Abbott Laboratories common stock at an exercise price of $33.76 per share, determined pursuant to a formula set forth in the Merger Agreement.
  • [F8]This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 6,154 shares of Abbott Laboratories common stock at an exercise price of $82.19 per share, determined pursuant to a formula set forth in the Merger Agreement.
  • [F9]This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,205 shares of Abbott Laboratories common stock at an exercise price of $93.11 per share, determined pursuant to a formula set forth in the Merger Agreement.

Documents

1 file

Issuer

ABBOTT MEDICAL OPTICS INC

CIK 0001168335

→
Entity typeother

Related Parties

1
  • filerCIK 0001227310

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 8:04 PM ET
Size
50.3 KB
View on SEC.gov